Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05424783 · ClinicalTrials.gov registry record
MRI And GPS Informing Choices for Prostate Cancer Treatment (MAGIC)
A clinical trial of Prostate Cancer, sponsored by Northwestern University.
- Recruiting
- Registry status
- 222
- Enrollment target
- 2
- Study locations
NCT05424783 is a study of Prostate Cancer that is actively recruiting participants, run by Northwestern University. The registered enrollment target is 222 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (63% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT05424783, a study of Prostate Cancer, is actively recruiting participants, sponsored by Northwestern University.
- RECRUITING
- Registry status
- 222 participants
- Enrollment target
- 2
- Study locations
Study Summary
The overarching goal is to prospectively recruit men considering active surveillance for treatment in the MAGIC (MRI And GPS Informing Choices for prostate cancer treatment) Cohort to provide meaningful data on active surveillance in Blacks and in men served in safety net hospitals. Recent studies highlight significant promise for multi-parametric magnetic resonance imaging of the prostate (MRI) and Genomic Prostate Score assay (GPS) as tools to help risk stratify men on active surveillance to identify men likely to harbor undetected aggressive disease in their prostate. Given the risk data provided by these modalities and the low adherence with monitoring common in men served in public hospitals, both tools may improve safety via improved patient selection and patient adherence with monitoring. The downside is that excessive testing may lead to too many false positives and unnecessary treatment. Two hundred men with very low to intermediate risk prostate cancer were randomized into the 2-arm ENACT Clinical trial from 2016-2019 to study the impact of the GPS assay on treatment choice. Overall, 104 men received GPS assay and 96 controls did not receive the assay (a confirmatory test) right after being newly diagnosed with favorable risk prostate cancer. For Aim 1, 222 men will be recruited into the MRI And GPS Informing Choices for prostate cancer treatment (MAGIC) study and they will be given the GPS assay and multi-parametric MRI of the prostate to provide personalized risk data for having aggressive tumors in their prostate. Between the ENACT and MAGIC study, there will be 3 groups of men who will have received both GPS \& MRI, GPS alone, or neither test and can compare the impact of having 0,1 or 2 confirmatory tests on patient's adherence to active surveillance monitoring protocols over 18 months. The analyses will elucidate whether 1 or 2 tests are needed to improve adherence to monitoring. Monitoring is vital for detecting tumor progression early and avoiding
Conditions Studied
Interventions
- OTHER Genomic Prostate Score assay and Multi-parametric magnetic resonance imaging study of the prostate
Study Locations (2)
Illinois
- Northwestern University - Chicago
- University of Illinois at Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 222 participants |
| Start Date | 2022-10-15 |
| Est. Completion | 2025-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05424783
The ClinicalTrials.gov registry entry for NCT05424783 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 222 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (63% lower). The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Genomic Prostate Score assay and Multi-parametric magnetic resonance imaging study of the prostate is the first listed.
NCT05424783 reports 2 study locations spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT05424783 about?
NCT05424783 is a clinical study titled "MRI And GPS Informing Choices for Prostate Cancer Treatment (MAGIC)". The overarching goal is to prospectively recruit men considering active surveillance for treatment in the MAGIC (MRI And GPS Informing Choices for prostate cancer treatment) Cohort to provide meaningful data on active surveillance in Blacks and in men served in safety net hospitals. Recent studies h...
What is the current status of trial NCT05424783?
This trial is currently recruiting. The enrollment target is 222 participants. The study started on 2022-10-15. Estimated completion is 2025-12-31.
What conditions does trial NCT05424783 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT05424783?
The interventions under investigation include: Genomic Prostate Score assay and Multi-parametric magnetic resonance imaging study of the prostate (OTHER).
Who is sponsoring clinical trial NCT05424783?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05424783 being conducted?
This trial has 2 study locations across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy
RECRUITING
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.